Adkins, D., Wong, W., Misleh, J. G., Lorch, J. H., Grewal, J. S., Kerrigan, K. C., Russell, J. S., Cetnar, J. P., Ho, A. L., Chen, K., Llorin-Sangalang, J. D., Aysola, K., Thomas, J. S. (2025). Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.6048